Abstract Library

#4655 A novel nonpeptide drug conjugate (NDC) for the treatment of somatostatin receptor 2-expressing tumours

Introduction: Somatostatin receptor 2 (SST2) is an established target for the treatment of NETs and potentially other solid tumours.

Conference:

Presenting Author:

Authors: Zhao J, Sturchler E, Yang B, Chen M, Tang Y,

Keywords: somatostatin, solid tumour, drug conjugate, internalisation, cytotoxicity,

#4593 Excellent response to Ac-225 DOTATATE therapy in a patient with small cell lung cancer

Introduction: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for patients with NETs overexpressing somatostatin receptors (SSTR). IHC analysis indicates that up to 50% of small cell lung cancer (SCLC) tumours are SSTR2 positive and thus can be targeted by SSR imaging and PRRT. Therapy with α-emitting radionuclides, such as Ac225, may offer several advantages over β-emitters by having higher energy transfer and more effective cancer cell death.

Conference:

Presenting Author: Tuncel M

Authors: Tuncel M, Türkan C, Eryılmaz Y, Pala A, Kılıçkap S,

Keywords: Ac-225 DOTATATE, Small Cell lung cancer, PET, somatostatin receptor, PRRT,

#4569 Dramatic response to tarlatamab in a patient with metastatic primary small cell neuroendocrine carcinoma of the breast

Introduction: Primary small cell neuroendocrine carcinoma of the breast (SCNCB) is a rare malignancy with a poor prognosis. Tarlatamab, a DLL3-targeted bispecific T-cell engager, is FDA-approved for extensive-stage small cell lung carcinoma.

Conference:

Presenting Author: Patel D

Authors: Patel D, Alahmadi A, Maddocks K, Lampert B, Giglio P,

Keywords: tarlatamab, small cell neuroendocrine carcinoma of the breast,

#4472 Paraneoplastic cerebellar degeneration relates to lung neuroendocrine tumour

Introduction: Neurological Paraneoplastic syndromes related to cancer are infrequently,

Conference:

Presenting Author:

Authors: González Devia D, Roa Culma L, Martínez Rubio C, Zafra Sierra M, Cañon Solano D,

Keywords: Paraneoplastic Syndrome, Paraneoplastic Cerebellar Degeneration, Neuroendocrine Tumour, Lung Neuroendocrine Tumour, CARP 8 antibody,

#4432 Prostatic small cells carcinoma: A case report

Introduction: Small cells prostate carcinoma is a rare entity with bad prognosis. It can be pure, diagnosed denovo, or mixed with adenocarcinoma. Platinum based chemotherapy remains the main therapeutic arm.

Conference:

Presenting Author:

Authors: Boukerzaza I, Zerrouk D, Laouar N, Filali T,

Keywords: prostate, small cell, carcinoma, chemotherapy,